Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...